{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.2","upperLimit":"27.5","value":"9.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Patients were evaluated for non-relapse mortality (NRM) throughout the study. Non-relapse mortality was considered any death not attributable to relapse or disease progression. The cumulative incidence of NRM was determined using competing risk analysis. Competing risks for NRM were death due to disease progression, relapse and nonengraftment.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients were analyzed as a single population. Stratification by conditioning regimen was not done.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 day point estimate was provided","title":"Non-relapse Mortality at 100 Days Post HSCT","type":"SECONDARY","unitOfMeasure":"Percentage of patients with a NRM"}